Efficiency of low dosage apatinib in post-first-line treatment of advanced lung adenocarcinoma

Da-Xiong Zeng; Chang-Guo Wang; Wei Lei; Jian-An Huang; Jun-Hong Jiang

doi:10.18632/oncotarget.19908

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Efficiency of low dosage apatinib in post-first-line treatment of advanced lung adenocarcinoma

Da-Xiong Zeng, Chang-Guo Wang, Wei Lei, Jian-An Huang and Jun-Hong Jiang _

PDF | HTML | How to cite

Oncotarget. 2017; 8:66248-66253. https://doi.org/10.18632/oncotarget.19908

Metrics: PDF 1449 views | HTML 2427 views | ?

Abstract

Da-Xiong Zeng1,*, Chang-Guo Wang1,*, Wei Lei1, Jian-An Huang1 and Jun-Hong Jiang1

1Department of Respiratory and Critical Care, The First Affiliated Hospital of Soochow University, Suzhou, China

*These authors have contributed equally to this work

Correspondence to:

Jun-Hong Jiang, email: [email protected]

Keywords: lung cancer, apatinib, adenocarcinoma, VEGFR-2, EGFR wild-type

Received: March 29, 2017 Accepted: June 30, 2017 Published: August 03, 2017

ABSTRACT

Chemotherapy is the standard treatment of in advanced lung adenocarcinoma patients without driver mutation. However, few drugs could be selected when diseases progressed after second-line treatment. As a small molecule inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2), apatinib was suggested mainly using in advanced gastric cancer. In this study, we showed the results of apatinib as second-line to fourth-line treatment in EGFR wild-type advanced lung adenocarcinoma patients. 16 EGFR wild-type advanced lung adenocarcinoma patients were administrated apatinib (250-500 mg/d) orally. 3 patients showed partial response and 8 patients showed stable diseases response to apatinib, with a medium progression-free survival (PFS) of 4.4 month (2-10 months). The objective remission rate (ORR) was 18.75%(3/16). The total disease control rate (DCR) was 68.75% (11/16). The main toxicities were hypertension, hand-foot syndrome, proteinuria and thrombocytopenia which were tolerable and manageable. So, apatinib might be an optional choice for post-first-line treatment of EGFR wild-type advanced lung adenocarcinoma patients.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19908

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

Efficiency of low dosage apatinib in post-first-line treatment of advanced lung adenocarcinoma

Abstract